Personalized medicine is partly based on biomarker-guided diagnostics, therapy and prognosis, which is becoming an unavoidable immunosorbent assay (ELISA) measurements. However, a multiplex multimarker approach cannot become a generally disseminated
Introduction
We are living in a time of large clinical trials, and evidencebased medicine seems to be the dominant therapeutic approach to patients with cardiovascular disease. On the other hand, we are becoming aware that any population is different from the subset of patients in clinical trials given that the average patient is older, suffers from a wide variety of non-cardiovascular disorders and takes a number of different therapies that interfere with cardiovascular treatment. Thus, personalized medicine is a broad and rapidly spreading concept of medicine in the 21 st -sonalized medicine is considered to be the tailoring of medical treatment to the special characteristics of an individual patient.
The principle aim is not to create drugs or treatment strategies approach to the individual patient (or group of patients) based on the precise characterization of his pathologic condition or -who will not [1] . To date, the use of personalized medicine in eg, genetic diseases, pharmacogenomics and biomarker research [2] revealed polymorphisms affecting responses to various drugs, -susceptibility has been established in clinical practice.
only serve as principle biomarkers in the diagnosis of heart Moreover, the vasodilator and diuretic natures of natriuretic peptides are being considered in clinical trials.
-Findings of increased levels of tumor necrosis factor induced sophisticated approaches to reduce inflammation (now considered an important goal in the pathophysiology of a failing heart), such as transcriptional/translational approaches, targeted anticytokine treatment or immunomodulation background of the particular cardiovascular disorder may -biomarkers are circulating molecules that should provide pathophysiologic insights and aid to establish a diagnosis, -the severity of the disease. The ideal biomarker helps in clinical decision making, and its levels are reduced with effective -ies is limited in general given that they focus on individual biomarkers representing only one of several features within a particular pathologic condition [3, 4] comprehensive information on the pathologic mechanisms underlying the various alterations of the diseased cardiovas--tosis, or neurohumoral activation, resulting in hypertension, -ity of cardiovascular biomarkers involves combining multiple markers into a multimarker panel to increase their diagnostic and prognostic value in the setting of primary or secondary prevention [5] .
Two methodological multimarker panel approaches
Two basic assay formats have been developed to facilitate dimensional array (Biochip Array Technology capture antibodies are conjugated to different populations of microbeads that can be distinguished by their fluorescence intensity in a flow cytometer (Luminex [6] .
Biochip Array Technology
This method works by combining a panel of related tests on a single biochip with a single set of reagents, controls and calibrators ( Figure 1 ). Only one single undivided sample is used.
holds an individual test. Thus, 23 tests can be performed, with two reserved for internal quality control, representing another [6] .
immunoassays. This technique involves 100 distinctly colored -analytes from a sample (Figure 2) . The use of different colored beads enables the simultaneous detection of many analytes is used to determine the different assays by bead colors and --tions of analysis, cost and time savings, and the comprehensive information obtained about the pathologic process [6] .
Experimental studies using a multiplex biomarker approach -genesis of cardiovascular disease that can simultaneously --von Willebrand Factor (vWF). To the best of our knowledge, cardiology studies in our laboratory. We aimed to evaluate the relationship of selected biomarkers describing the remodeling process of the hypertensive heart in L -tension in two subsequent periods of hypertension development (4 and 7 weeks of L cTnT was markedly increased in L with the control [7] rats [8] .
cardiology have predominantly focused on cytokine spectrum mapping. Four murine animal models of various cardiovascular pathologies (banding of the ascending aorta or the pulmonary artery, myocardial infarction and a cardiomyopathy model with inducible cardiomyocyte-specific knockout of 2+ -kines is dependent on the etiology of myocardial hypertro- Clinical studies using a multimarker panel approach aspects of the pathologic process but have gradually started to include serial measurement of biomarkers to provide a more biomarkers from distinct pathophysiological pathways can overcome some of the limitations of single marker measure--tions of biomarkers for the prediction of both primary and secondary cardiovascular disease presented statistically sigin prediction compared with a model with traditional risk factors [10] . et al [11] evaluated thirty biomarkers from different pathophysiological pathways (lipid metabolism, inflam--tive stress, coagulation, renal function, angiogenesis, and myobiomarker consistently improved the risk estimation. How-10-year risk estimation for cardiovascular events.
nation of distinct sources and types of data. Historically, prediction models have relied on a limited number of specified -els may function in populations but not in individual patients.
come directly from a full range of associations and interactions among the data. The computer algorithm creates a unique phenotype by processing all of the data sources, compares the phenotype with numerous additional patients, suggests the patient's diagnosis, and indicates individualized risk contributing to decision making for therapeutic options [12] . Halim et al [13] the association of circulating proteins with the risk of death or -people underwent invasive coronary angiography at baseline. The investigators used techniques such as penalized logistic -model conditioned to include all clinical risk factors, only with simultaneous evaluation of biomarkers and clinical risk factors, all 6 biomarkers were retained [14] . Furthermore, serum samples from 8401 participants in the were to determine whether insulin glargine-mediated normoglycemia can reduce cardiovascular morbidity and/or mortality in people at high risk for vascular disease with either identified in patients with dysglycemia that were each inde- [15] composite outcomes, including heart failure hospitalization risk marker, was consistently identified in all analyses and perhaps serves as a good positive control, angiopoeitin-2 and across multiple different modeling conditions, suggesting that these proteins may represent biological pathways contributing [16] . step, the antigen binds to the antibody. Then, a second antibody or conjugate is added, and the conjugate is labeled with an enzyme soluble substrate to produce a chemiluminescent signal.
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Acta Pharmacologica Sinica et al [17] is becoming popular, it must be emphasized that systematic such studies are eagerly awaited.
studies, eg, the type of population investigated, the biomarkers tested and their timing, the duration of follow-up, the choice of primary and secondary endpoints in a particular clinical study, and the statistical methods used [10] are several challenges to overcome prior to the widespread biomarker validation and standardization of immunoassay methods for transformation of raw data into diagnostic results [18] .
Future perspectives -tion of diagnosis, treatment and prognosis in patients with caraim should be to identify an optimal combination of already well-established biomarkers in such a way that could yield the most comprehensive and precise information on cardioand dynamic nature of pathologic processes and offer substanmeasurements. The multimarker strategy involves employing a set of pathophysiologically different biomarkers and their interplay such that each marker may contribute independently by providing complementary or additional information, which represents a sophisticated approach to individualizing pharmacological intervention and outcome prediction. However, -ally disseminated method until analytical problems are solved accomplished.
should implement biomarkers respecting the following attri-1) The principle biomarker for the determination of diagnosis have to be addressed.
2) The biomarker (or a combination of them) characterizing the severity of the disease and the prognostic implications ought -tic interventions should be suggested.
which is valuable in the advanced period of the particular disease, could be delineated.
Conclusions
How the measurement of multiple prognostic or diagnostic biomarkers should be implemented into modern clinical pracprinciple questions of future studies. This perspective has no ambition to serve as an overview of the current topic. The goal wider conceptual framework under the bilateral interactions cooperation of pathophysiologists, clinicians and biochemists is necessary for the implementation of a personalized -ment of various cardiovascular pathologies in everyday clinical practice, and this approach could serve as a logical partner of population-based evidence in large clinical trials.
